Personalis’ NeXT Personal minimal residual disease (MRD) assay gained expanded Medicare coverage under MolDX, extending reimbursement to immunotherapy monitoring across late-stage solid tumors. The company said the decision was supported by evidence from work with Spain’s Vall d’Hebron Institute of Oncology, where the assay’s circulating tumor DNA signal was linked to ongoing surveillance, treatment response, and clinical outcomes during immunotherapy. NeXT Personal previously received Medicare coverage for recurrence monitoring in specific cancers, including stage II to III breast cancer and stage I to III non-small cell lung cancer. Analyst commentary suggests the IO reimbursement level could be similar to other reimbursed indications, potentially improving revenue and margin assumptions. This is a practical reimbursement step that could accelerate adoption among oncology programs seeking MRD-informed decision-making during active treatment rather than only after recurrence monitoring.